
OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial
Hertzel C. Gerstein, Zhuoru Li, Chinthanie Ramasundarahettige, et al.
Circulation (2023) Vol. 147, Iss. 13, pp. 1004-1013
Open Access | Times Cited: 18
Hertzel C. Gerstein, Zhuoru Li, Chinthanie Ramasundarahettige, et al.
Circulation (2023) Vol. 147, Iss. 13, pp. 1004-1013
Open Access | Times Cited: 18
Showing 18 citing articles:
Comparison of the efficacy and safety of GLP ‐1 receptor agonists on cardiovascular events and risk factors: A review and network meta‐analysis
Xuedong An, WenJie Sun, Zhige Wen, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access | Times Cited: 1
Xuedong An, WenJie Sun, Zhige Wen, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access | Times Cited: 1
Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes
Patrizia Natale, Suetonia C. Green, David J. Tunnicliffe, et al.
Cochrane library (2025) Vol. 2025, Iss. 2
Closed Access | Times Cited: 1
Patrizia Natale, Suetonia C. Green, David J. Tunnicliffe, et al.
Cochrane library (2025) Vol. 2025, Iss. 2
Closed Access | Times Cited: 1
Glucagon-like peptide-1 receptor agonists and stroke: A systematic review and meta-analysis of cardiovascular outcome trials
Anastasia Adamou, Fotios Barkas, Haralampos Milionis, et al.
International Journal of Stroke (2024) Vol. 19, Iss. 8, pp. 876-887
Closed Access | Times Cited: 8
Anastasia Adamou, Fotios Barkas, Haralampos Milionis, et al.
International Journal of Stroke (2024) Vol. 19, Iss. 8, pp. 876-887
Closed Access | Times Cited: 8
Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists
John W. Ostrominski, Scott D. Solomon, Muthiah Vaduganathan
European Heart Journal (2024) Vol. 45, Iss. 30, pp. 2748-2751
Closed Access | Times Cited: 7
John W. Ostrominski, Scott D. Solomon, Muthiah Vaduganathan
European Heart Journal (2024) Vol. 45, Iss. 30, pp. 2748-2751
Closed Access | Times Cited: 7
Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials
D Gomes, J Presume, Pedro de Araújo Gonçalves, et al.
Cardiovascular Drugs and Therapy (2024)
Closed Access | Times Cited: 4
D Gomes, J Presume, Pedro de Araújo Gonçalves, et al.
Cardiovascular Drugs and Therapy (2024)
Closed Access | Times Cited: 4
Research Advances in Fusion Protein-Based Drugs for Diabetes Treatment
Wen-Ying Deng, Z Zhao, Tao Zou, et al.
Diabetes Metabolic Syndrome and Obesity (2024) Vol. Volume 17, pp. 343-362
Open Access | Times Cited: 4
Wen-Ying Deng, Z Zhao, Tao Zou, et al.
Diabetes Metabolic Syndrome and Obesity (2024) Vol. Volume 17, pp. 343-362
Open Access | Times Cited: 4
Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity
Matthew M.Y. Lee, Nazim Ghouri, Anoop Misra, et al.
Diabetes Care (2025) Vol. 48, Iss. 3, pp. 489-493
Open Access
Matthew M.Y. Lee, Nazim Ghouri, Anoop Misra, et al.
Diabetes Care (2025) Vol. 48, Iss. 3, pp. 489-493
Open Access
Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists
Jake Chen, Cooper Me, Coughlan Mt
Diabetes & Metabolism (2025), pp. 101641-101641
Closed Access
Jake Chen, Cooper Me, Coughlan Mt
Diabetes & Metabolism (2025), pp. 101641-101641
Closed Access
Kardiovaskuläre Risikoreduktion durch GLP-1-Rezeptor-Agonisten in der asiatischen und weißen Bevölkerung
S. Kahl
Deleted Journal (2025)
Closed Access
S. Kahl
Deleted Journal (2025)
Closed Access
Novel pharmacological interventions for diabetic kidney disease
Seng Kiong Tan, Jairo A Pinzón-Cortés, Mark E. Cooper
Current Opinion in Nephrology & Hypertension (2023) Vol. 33, Iss. 1, pp. 13-25
Closed Access | Times Cited: 5
Seng Kiong Tan, Jairo A Pinzón-Cortés, Mark E. Cooper
Current Opinion in Nephrology & Hypertension (2023) Vol. 33, Iss. 1, pp. 13-25
Closed Access | Times Cited: 5
Peptide GLP-1 receptor agonists: From injection to oral delivery strategies
Zhiqiang Ke, Qianqian Ma, Xiaonan Ye, et al.
Biochemical Pharmacology (2024) Vol. 229, pp. 116471-116471
Closed Access | Times Cited: 1
Zhiqiang Ke, Qianqian Ma, Xiaonan Ye, et al.
Biochemical Pharmacology (2024) Vol. 229, pp. 116471-116471
Closed Access | Times Cited: 1
Treatment of type 2 diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, et al.
Deleted Journal (2024) Vol. 20, Iss. 2, pp. 212-260
Closed Access | Times Cited: 1
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, et al.
Deleted Journal (2024) Vol. 20, Iss. 2, pp. 212-260
Closed Access | Times Cited: 1
Therapy of Type 2 Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, et al.
Experimental and Clinical Endocrinology & Diabetes (2024) Vol. 132, Iss. 07, pp. 340-388
Open Access | Times Cited: 1
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, et al.
Experimental and Clinical Endocrinology & Diabetes (2024) Vol. 132, Iss. 07, pp. 340-388
Open Access | Times Cited: 1
Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease
Tianyu Wang, Juncan Ding, Xinyi Cheng, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Tianyu Wang, Juncan Ding, Xinyi Cheng, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Emerging Medical Therapies for the Treatment of Obesity in Women with Cardiovascular Diseases
Leili Behrooz, Carrie G. Lenneman, Naomi M. Hamburg
Current Cardiology Reports (2023) Vol. 25, Iss. 11, pp. 1475-1488
Open Access | Times Cited: 3
Leili Behrooz, Carrie G. Lenneman, Naomi M. Hamburg
Current Cardiology Reports (2023) Vol. 25, Iss. 11, pp. 1475-1488
Open Access | Times Cited: 3
Risk Stratification and Treatment of Obesity for Primary and Secondary Prevention of Cardiovascular Disease
John W. Ostrominski, Tiffany M. Powell‐Wiley
Current Atherosclerosis Reports (2023)
Closed Access | Times Cited: 3
John W. Ostrominski, Tiffany M. Powell‐Wiley
Current Atherosclerosis Reports (2023)
Closed Access | Times Cited: 3
Incretin and glucagon receptor polypharmacology in chronic kidney disease
Brandon E. McFarlin, Kevin L. Duffin, Anish Konkar
AJP Endocrinology and Metabolism (2024) Vol. 326, Iss. 6, pp. E747-E766
Open Access
Brandon E. McFarlin, Kevin L. Duffin, Anish Konkar
AJP Endocrinology and Metabolism (2024) Vol. 326, Iss. 6, pp. E747-E766
Open Access
Evaluating the impact of efpeglenatide on cardiometabolic and safety outcomes in individuals with diabetes: a systematic review and meta-analysis
Shurjeel Uddin Qazi, Huzaifa Ul Haq Ansari, Zoaib Habib Tharwani, et al.
Journal of Diabetes & Metabolic Disorders (2024) Vol. 23, Iss. 1, pp. 405-415
Closed Access
Shurjeel Uddin Qazi, Huzaifa Ul Haq Ansari, Zoaib Habib Tharwani, et al.
Journal of Diabetes & Metabolic Disorders (2024) Vol. 23, Iss. 1, pp. 405-415
Closed Access